Emergent BioSolutions (NYSE:EBS) Stock Price Up 7.2% – Should You Buy?

Emergent BioSolutions Inc. (NYSE:EBS) shares traded up 7.2% during trading on Wednesday . The company traded as high as $10.95 and last traded at $10.96. 908,581 shares changed hands during mid-day trading, a decline of 7% from the average session volume of 972,512 shares. The stock had previously closed at $10.22.

Wall Street Analyst Weigh In

EBS has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a research note on Tuesday. StockNews.com upgraded Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Finally, Benchmark lifted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th.

Emergent BioSolutions Stock Up 1.2 %

The stock has a market cap of $629.19 million, a P/E ratio of -2.83 and a beta of 1.60. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The company has a 50-day simple moving average of $9.39 and a two-hundred day simple moving average of $9.31.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.88. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The business had revenue of $293.80 million during the quarter, compared to analysts’ expectations of $328.72 million. During the same quarter in the prior year, the company posted ($1.44) EPS. On average, equities analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Institutional Investors Weigh In On Emergent BioSolutions

Institutional investors and hedge funds have recently bought and sold shares of the business. Stifel Financial Corp bought a new position in shares of Emergent BioSolutions during the third quarter valued at approximately $96,000. FORA Capital LLC bought a new position in Emergent BioSolutions in the 3rd quarter worth $103,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Emergent BioSolutions in the 2nd quarter worth about $93,000. Landscape Capital Management L.L.C. bought a new stake in shares of Emergent BioSolutions during the 3rd quarter valued at about $141,000. Finally, Entropy Technologies LP purchased a new position in shares of Emergent BioSolutions during the third quarter valued at about $155,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.